PharmaTelevision - EUSA Pharma: Strategies of a Speciality Company

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: EUSA Pharma: Strategies of a Speciality Company

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Bryan Morton, Founder and CEO of EUSA Pharma. Bryan begins by discussing the establishment of EUSA Pharma, and how its formation was motivated by the successful acquisition of Zeneus Pharma (also founded by Bryan), by Cephalon in 2005. Bryan talks about the three speciality pharma models employed by EUSA, the similiarities and differences between the US and Europe speciality pharma and the reason for basing EUSA in the US. He also talks about EUSA’s strategy in Europe versus the strategies of the more traditional, private European mid-sized companies. Bryan speculates on the future of speciality pharma companies, and of EUSA in particular. The interview ends with a discussion of EUSA’s pending acquisition of US company Cytogen, and EUSA’s strategy with regard to further acquisitions.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Establishment of EUSA Pharma, and how its formation was motivated by the successful acquisition of Zeneus Pharma.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in London. On this show I have Bryan Morton, who is CEO of EUSA Pharma based here in the UK, but actually headquartered in the US, welcome to the show.

Bryan Morton:

Thank you Fintan Walton, nice to be here.

Fintan Walton:

Good. Bryan Morton, you are a serial entrepreneur, your origins come from the traditional pharmaceutical industry and you've worked there, but I suppose your profile is risen significantly particularly here in the UK and amongst the investment community because you are involved in the acquisition of some of the Elan's oncology products into a company called Zeneus Pharma and that company was backed by Apax and you've managed to sell it several years later for three times, I know that makes companies like Apax extremely pleased, you sold it to Cephalon based in the US?

Bryan Morton:

That's right.

Fintan Walton:

And now you are a CEO of EUSA Pharma and you are doing it again why?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Bryan Morton

Founder

Bryan Morton has a BSc in Pharmacology from Aberdeen University and a MBA from Durham University. He began his pharmaceutical career in sales, and has held positions of increasing responsibility in medical information, marketing, sales management, business development and general management during a 30-year career in the healthcare industry, largely with Merck and Co and Bristol Myers Squibb. During this time Bryan Morton has lived and worked in the UK, the US, Australia and Belgium, and in 2003 he founded Zeneus Pharma through the acquisition of Elan's European sales and marketing business for US$120 M in a private equity deal. Following the sale of Zeneus Pharma for US$360 M in late 2005, Bryan Morton founded EUSA Pharma in 2006, with backing from Essex Woodlands Health Ventures.

EUSA Pharma

EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It was been built through the acquisition of Talisker Pharma in July 2006, and of OPi in March 2007. The company's primary marketed products Erwinase,Rapydan, Kidrolase, Fomepizole and Xenazine, are focused on the areas of oncology, pain control and critical care. In addition, EUSA Pharma has an active late-stage development pipeline, which includes candidates targeting rheumatoid arthritis and Alzheimer's disease, schizophrenia, the prevention and treatment of infected skin ulcers, and local post-surgical pain control.